Trial Profile
"Evaluation of molecular response to treatment with Heberprot-P in patients with diabetic foot ulcers".
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Recombinant epidermal growth factor (Primary)
- Indications Diabetic foot ulcer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms HeberproGen
- 14 Sep 2011 New trial record